Compare HUDI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | JSPR |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | China | United States |
| Employees | N/A | 22 |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.9M |
| IPO Year | 2019 | N/A |
| Metric | HUDI | JSPR |
|---|---|---|
| Price | $0.90 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 431.2K | ★ 705.5K |
| Earning Date | 01-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.42 |
| 52 Week High | $5.46 | $7.19 |
| Indicator | HUDI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 34.19 |
| Support Level | $0.75 | $0.42 |
| Resistance Level | $1.35 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.76 | 25.07 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.